Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
This study has been completed.
Memorial Hospital of Rhode Island
Roger Williams Medical Center
Information provided by (Responsible Party):
howard safran, Brown University
First received: July 15, 2008
Last updated: June 26, 2014
Last verified: June 2014
This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
||Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Primary Outcome Measures:
- Response Rate by Recist Criteria [ Time Frame: on average about every 2 months until progression, on average about 4 months. ]
radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD
It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2013 (Final data collection date for primary outcome measure)
25 mg po qd x 21 days then 1 week off equals one cycle
Other Name: revlimid
This study will determine the response rate and toxicities of lenalidomide as second line treatment for patients with liver cancer who have progressed after sorafenib.
|Ages Eligible for Study:
||19 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Pathologically confirmed HCC or triple phase CT consistent with HCC in a patient with known cirrhosis and AFP > 200 ng/ml.
- Disease not amenable to curative surgical resection
- Patients must have been previously treated with sorafenib. Patients who are unable to receive sorafenib due to financial reasons are also eligible.
- All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
- No previous thalidomide.
- Patients must have radiologically assessable tumor.
- ECOG performance status of 0-2 at study entry.
- Understand and voluntarily sign an informed consent form.
- Age >18 years at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
Laboratory test results within these ranges:
- Absolute neutrophil count > 1000/mm3
- Platelet count > 60,000/mm3
- Serum creatinine > 2.0 mg/dL
- Total bilirubin > 4 mg/dL
- AST (SGOT) and ALT (SGPT) > 5 x ULN.
- Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix: H Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix: F Education and Counseling Guidance Document
- Disease free of prior malignancies for > 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Known hypersensitivity to thalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Any prior use of lenalidomide.
- Concurrent use of other anti-cancer agents or treatments.
- Known positive for HIV. (The effect of immune modulation of lenalidomide on patients who are HIV positive is unknown).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00717756
|Montefiore Medical Center
|Bronx, New York, United States, 10467 |
|Memorial Hospital of Rhode island
|Pawtucket, Rhode Island, United States, 02860 |
|Providence, Rhode Island, United States, 02903 |
Memorial Hospital of Rhode Island
Roger Williams Medical Center
||Howard Safran, MD
Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.
||howard safran, Principle Investigator, Brown University
History of Changes
|Other Study ID Numbers:
Celgene # RV-HCC-PI- 0159 ( Other Identifier: brown university )
celgene ( Other Identifier: brown university )
|Study First Received:
||July 15, 2008
|Results First Received:
||February 20, 2014
||June 26, 2014
Keywords provided by howard safran, Brown University:
liver cancer, second line
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Physiological Effects of Drugs
Angiogenesis Modulating Agents